Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07259317 · ClinicalTrials.gov registry record · Phase 2
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
A Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT07259317 is a Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 60 participants, below the 94-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT07259317, a Phase 2 study of Adenocarcinoma and Carcinoma, Pancreatic Ductal, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DRUG Relacorilant 150 mg once daily (QD)
- DRUG Nab-paclitaxel 100 mg/m^2
- DRUG Gemcitabine 1000 mg/m^2
Study Locations (4)
Arizona
- Site 02 - Scottsdale
California
- Site 04 - Los Angeles
Michigan
- Site 03 - Grand Rapids
Texas
- Site 01 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07259317
The ClinicalTrials.gov registry entry for NCT07259317 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 94-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (36% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Relacorilant 150 mg once daily (QD) is the first listed.
NCT07259317 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT07259317 about?
NCT07259317 is a clinical study titled "Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma". This is a Phase 2, single-arm study to evaluate the safety and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (PDAC).
What is the current status of trial NCT07259317?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-01-27. Estimated completion is 2027-07.
What conditions does trial NCT07259317 study?
This clinical trial studies the following conditions: Adenocarcinoma, Carcinoma, Pancreatic Ductal.
What interventions are being tested in trial NCT07259317?
The interventions under investigation include: Relacorilant 150 mg once daily (QD) (DRUG), Nab-paclitaxel 100 mg/m^2 (DRUG), Gemcitabine 1000 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT07259317?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07259317 being conducted?
This trial has 4 study locations across Arizona, California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
COMPLETED · Phase 2
-
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.